<DOC>
	<DOCNO>NCT02072317</DOCNO>
	<brief_summary>The purpose study evaluate compare safety effectiveness Chemotherapy Paclitaxel plus raltitrexed plug compare taxol second-line treatment advance gastric cancer</brief_summary>
	<brief_title>Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment Advanced Gastric Cancer</brief_title>
	<detailed_description>first cycle treatment ( day one ) two month last cycle</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1.18~75 year old 2.Pathological diagnosis gastric cancer gastroesophageal junction adenocarcinoma 3.patient fail The first line treatment 5Fu platinum , patient relapse half year use 5 Fu platinum Postoperative adjuvant chemotherapy 4.ECOG 01 5.At least one measurable objective tumor lesion 6.ANC≥1.5*109/L；PLT≥80*109/L；HB≥90g/L；TBI≤1.5 ( UNL ) ; ALT、AST≤1.5ULN； Cr≤ULN；Ccr≥60ml/min 7.Expected survival period 3 month 8. patient voluntary participation , sign inform consent 1 . Recurrence transfer receive taxol docetaxel firstline chemotherapy , If adjuvant chemotherapy paclitaxel , From last chemotherapy 6 month less 2 . With uncontrollable large pleural peritoneal effusion 3 . In near future history myocardial infarction ( 3 month ) 4 . Malignant tumour past five year organization source , full treatment cervical carcinoma situ except skin basal cell carcinoma squamous cell carcinoma ; 5 . With brain metastasis 6 . Severe uncontrolled medical disease acute infection 7 . Pregnancy breastfeed woman 8 . Has long history chronic diarrhea , complete intestinal obstruction patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>PFS</keyword>
</DOC>